Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. [electronic resource]
Producer: 20070511Description: 63 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor
- Breast Neoplasms -- chemistry
- Chemotherapy, Adjuvant
- Cohort Studies
- Combined Modality Therapy
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic
- Genes, bcl-2
- Humans
- Ki-67 Antigen -- analysis
- Lymph Node Excision
- Mastectomy, Modified Radical
- Mastectomy, Segmental
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Paclitaxel -- administration & dosage
- Prognosis
- Proto-Oncogene Proteins c-bcl-2 -- analysis
- Radiotherapy, Adjuvant
- Receptor, ErbB-2 -- analysis
- Receptors, Estrogen -- analysis
- Receptors, Progesterone -- analysis
- Survival Analysis
- Tamoxifen -- administration & dosage
- Tumor Suppressor Protein p53 -- analysis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.